PMID- 28190020
OWN - NLM
STAT- MEDLINE
DCOM- 20170608
LR  - 20231112
IS  - 1643-3750 (Electronic)
IS  - 1234-1010 (Print)
IS  - 1234-1010 (Linking)
VI  - 23
DP  - 2017 Feb 12
TI  - Oxaliplatin and Infliximab Combination Synergizes in Inducing Colon Cancer 
      Regression.
PG  - 780-789
AB  - BACKGROUND Colon cancer is one of the most common malignant cancers and causes 
      millions of deaths each year. There are still no effective treatments for colon 
      cancer patients who are at advanced stage. Tumor necrosis factor-alpha (TNF-alpha) 
      might be a good therapy target due to its widely-accepted roles in regulating 
      multiple important biological processes, especially in promoting inflammation. 
      MATERIAL AND METHODS We evaluated the expression of TNF-alpha in 108 human colon 
      cancer tissue samples and 2 colon cancer cell lines (CT26 and HCT116), and 
      analyzed its prognostic values. Further, we explored the roles and mechanism of 
      anti-TNF-alpha treatment in combination with chemotherapy in vitro and in vivo. 
      RESULTS We found that TNF-alpha was highly expressed in colon cancer cell lines. The 
      survival analysis and Cox regression analysis indicated that high TNF-alpha was an 
      independent adverse prognosticator of colon cancer. In addition, anti-TNF-alpha 
      treatment enhanced the effects of chemotherapy in the xenograft mouse model 
      through inducing ADCC and CDC effects. CONCLUSIONS We conclude that TNF-alpha is an 
      independent adverse prognosticator of colon cancer, and anti-TNF-alpha might benefit 
      colon cancer patients.
FAU - Li, Wenya
AU  - Li W
AD  - Department of Internal Medicine, Cancer Hospital of China Medical University 
      (Liaoning Cancer Hospital and Institute), Shenyang, Liaoning, China (mainland).
FAU - Xu, Jian
AU  - Xu J
AD  - Department of Colorectal Surgery, Cancer Hospital of China Medical University 
      (Liaoning Cancer Hospital and Institute), Shenyang, Liaoning, China (mainland).
FAU - Zhao, Jian
AU  - Zhao J
AD  - Department of Colorectal Surgery, Cancer Hospital of China Medical University 
      (Liaoning Cancer Hospital and Institute), Shenyang, Liaoning, China (mainland).
FAU - Zhang, Rui
AU  - Zhang R
AD  - Department of Colorectal Surgery, Cancer Hospital of China Medical University 
      (Liaoning Cancer Hospital and Institute), Shenyang, Liaoning, China (mainland).
LA  - eng
PT  - Journal Article
DEP - 20170212
PL  - United States
TA  - Med Sci Monit
JT  - Medical science monitor : international medical journal of experimental and 
      clinical research
JID - 9609063
RN  - 0 (Organoplatinum Compounds)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 04ZR38536J (Oxaliplatin)
RN  - B72HH48FLU (Infliximab)
SB  - IM
MH  - Animals
MH  - Antineoplastic Combined Chemotherapy Protocols/*pharmacology
MH  - Apoptosis/drug effects
MH  - Cell Line, Tumor
MH  - Colonic Neoplasms/*drug therapy/metabolism/pathology
MH  - Drug Synergism
MH  - Female
MH  - HCT116 Cells
MH  - Humans
MH  - Infliximab/administration & dosage/*pharmacology
MH  - Male
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Organoplatinum Compounds/administration & dosage/*pharmacology
MH  - Oxaliplatin
MH  - Prognosis
MH  - Tumor Necrosis Factor-alpha/metabolism
MH  - Xenograft Model Antitumor Assays
PMC - PMC5319445
COIS- Disclosure of conflict of interest None.
EDAT- 2017/02/13 06:00
MHDA- 2017/06/09 06:00
PMCR- 2017/02/12
CRDT- 2017/02/13 06:00
PHST- 2017/02/13 06:00 [entrez]
PHST- 2017/02/13 06:00 [pubmed]
PHST- 2017/06/09 06:00 [medline]
PHST- 2017/02/12 00:00 [pmc-release]
AID - 901880 [pii]
AID - 10.12659/msm.901880 [doi]
PST - epublish
SO  - Med Sci Monit. 2017 Feb 12;23:780-789. doi: 10.12659/msm.901880.